Keck School Faculty

Cheryl Kefauver

Cheryl Kefauver

Program Manager
Cancer Center
1441 Eastlake Ave Health Sciences Campus Los Angeles

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653) J Clin Oncol. 2019 10 10; 37(29):2682-2688. . View in PubMed

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia Blood. 2012 Jun 21; 119(25):6025-31. . View in PubMed

Dose escalation of lenalidomide in relapsed or refractory acute leukemias J Clin Oncol. 2010 Nov 20; 28(33):4919-25. . View in PubMed

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia J Clin Oncol. 2008 May 20; 26(15):2519-25. . View in PubMed

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia J Clin Oncol. 2007 Sep 01; 25(25):3884-91. . View in PubMed

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma Ann Surg Oncol. 2007 Aug; 14(8):2367-76. . View in PubMed

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity J Clin Oncol. 2005 May 20; 23(15):3404-11. . View in PubMed

Powered by SC CTSI
Go to Top